American Society of Radiologic Technologists Approves Sensus Healthcare’s SRT Systems for Continuing Education Units
August 05 2020 - 8:30AM
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company
specializing in highly effective, non-invasive treatments for both
oncological and non-oncological conditions, and the leading
provider of superficial radiotherapy (SRT), reports that the
American Society of Radiologic Technologists (ASRT) has approved
Sensus Healthcare’s SRT Systems for Continuing Education Units
(CEUs). The approval covers all three SRT systems offered by
Sensus, namely the SRT-100™, the SRT-100+™ and the SRT-100 Vision™,
and automatically recognizes Sensus Healthcare training as a
legitimate provider for CEUs.
The ASRT approval provides radiation therapists
Category A credits, with 4.5 CEUs for the SRT-100 and SRT 100+, and
6.5 CEUs for the SRT-100 Vision in-person clinical trainings
beginning September 1, 2020. Now that the ASRT has recognized
the Company’s training with CEUs, the American Registry of
Radiologic Technologists (ARRT) automatically recognizes Sensus
Healthcare training as a legitimate provider for CEUs. The
ARRT requires Registered Technologists to complete and report 24
credits of approved continuing education activities every two years
to maintain their registration.
“This determination by the ASRT complements
existing support by the radiotherapeutic community for SRT, and
follows last month’s American Society for Radiation Oncology’s
recommendation of SRT as the first-line alternative to surgery when
treating patients with non-melanoma skin cancer,” said Joe Sardano,
chairman and chief executive officer of Sensus Healthcare.
“By recognizing Sensus as a provider for CEUs, our SRT
systems can now enjoy further validation of the importance of SRT
for the treatment of non-melanoma skin cancer.”
“We're so excited to offer
radiation therapists who undergo our comprehensive clinical
training the ability to earn clinical education hours through the
ASRT. This recognition by such a notable national association
adds further legitimacy to the role of radiation therapists
administering superficial radiation treatments for our users,”
added Monica DiGioia, director of clinical applications of Sensus
Healthcare.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device
company specializing in highly effective, non-invasive,
minimally-invasive and cost-effective treatments for both
oncological and non-oncological conditions. The Sculptura™
modulated robotic brachytherapy radiation oncology system provides
targeted directional anisotropic radiation therapy (ART) and
brachytherapy utilizing our proprietary, state-of-the-art 3D Beam
Sculpting™ to treat patients undergoing cancer treatment during
surgery, or at the tumor site, fast and efficiently. Sensus also
offers its proprietary low-energy X-ray technology known as
superficial radiation therapy (SRT), which is the culmination of
more than a decade of research and development, to treat
non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™
and SRT-100 Vision™ systems. With its portfolio of innovative
medical device products, Sensus provides revolutionary treatment
options to enhance the quality of life of patients around the
world.
For more information, visit
www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are,
or may be deemed, ''forward-looking statements.'' In some cases
these forward-looking statements can be identified by the use of
forward-looking terminology including "believes," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could,"
"might," "will," "should," "approximately," "potential" or, in each
case, their negative or other variations thereon or comparable
terminology, although not all forward-looking statements contain
these words.
By their nature, forward-looking statements
involve risks and uncertainties because they relate to events,
competitive dynamics and healthcare, regulatory and scientific
developments, and depend on the economic circumstances that may or
may not occur in the future or may occur on longer or shorter
timelines than anticipated. Although we believe that we have a
reasonable basis for each forward-looking statement contained in
this press release, we caution you that forward-looking statements
are not guarantees of future performance and that our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate may differ
materially from the forward looking statements contained in this
press release, as a result of, among other factors: the
continuation and severity of the COVID-19 pandemic, including its
impact on sales and marketing; our ability to achieve and sustain
profitability; market acceptance of our product lines; our ability
to successfully commercialize our products; our ability to compete
effectively in selling our products and services, including
responding to technological change and cost containment efforts of
our customers; our need and ability to obtain additional financing
in the future; our ability to expand, manage and maintain our
direct sales and marketing organizations; our ability to obtain and
maintain intellectual property of sufficient scope to adequately
protect our products, and our ability to avoid infringing or
otherwise violating the intellectual property rights of third
parties; the willingness of healthcare providers to purchase our
products if coverage, reimbursement and pricing from third party
payors for procedures using our products declines; the level and
availability of government and third party payor reimbursement for
clinical procedures using our products; our ability to effectively
manage our anticipated growth, including hiring and retaining
qualified personnel; the regulatory requirements applicable to us
and our competitors; our ability to manufacture our products to
meet demand; our current reliance on third party manufacturers and
sole- or single-source suppliers, as well as our ability to
successfully transition manufacturing of our products in-house; our
ability to reduce the per unit manufacturing costs; our ability to
efficiently manage our manufacturing processes; the regulatory and
legal risks, and certain operating risks, that our international
operations subject us to; the fact that product quality issues or
product defects may harm our business; the accuracy of our
financial statements and accounting estimates, including allowances
for accounts receivable and inventory obsolescence; any product
liability claims; new legislation, administrative rules, or
executive orders, including those that impact taxes and
international trade regulation; concentration of our customers in
the U.S. and China, including the concentration of sales to one
particular customer in the U.S.; and other risks described from
time to time in Sensus Healthcare's filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
In addition, even if our results of operations,
financial condition and liquidity, and the development of the
industry in which we operate are consistent with the
forward-looking statements contained in this press release, they
may not be predictive of results or developments in future periods.
Any forward-looking statements that we make in this press release
speak only as of the date of such statement, and we undertake no
obligation to update such statements to reflect events or
circumstances after the date of this press release. You should read
carefully our "Cautionary Note Regarding Forward-Looking
Information" and the factors described in the "Risk Factors"
section of our periodic reports filed with the Securities and
Exchange Commission to better understand the risks and
uncertainties inherent in our business.
Contact: LHA Investor
RelationsKim Sutton Golodetz212-838-3777kgolodetz@lhai.com
# # #
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
From Sep 2023 to Sep 2024